MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More
Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Read More
Differential gene expression and clinical utility of MammaPrint and BluePrint in male breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Read More
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
PUBLICATION: SABCS 2020 AUTHORS: Laura Lee, Sami Diab, Julie Read More
Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
PUBLICATION: SABCS 2020 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Read More
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS: Iris Noordhoek, Esther Bastiaannet, Ersan Read More
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial
PUBLICATION: SABCS 2020 AUTHORS:Ian E Krop, Lorenza Mittempergher, Joseph N Read More
MammaPrint Guides Treatment Decisions in Breast Cancer: Results of the IMPACt Trial
Publication: Soliman et al. BMC Cancer (2020) 20:81 Authors: Read More
